Home › Free Stock Grades › RGNX
REGENXBIO Inc. (RGNX) Stock Grade
RGNX · Healthcare
A
Market Cap
$742.7M
P/E Ratio
—
Revenue Growth (YoY)
+104.5%
Net Margin
-113.8%
Return on Equity
—
Dividend Yield
None
About REGENXBIO Inc.'s fundamentals
REGENXBIO Inc. is a biotechnology company with a market capitalization of $742.7 million that reported exceptional revenue growth of 104.5% year-over-year, indicating strong commercial traction. However, the company is currently unprofitable, with a net margin of -113.8%, meaning it is spending more than $1.13 for every dollar of revenue generated. The company does not pay a dividend, which is typical for growth-stage biotech firms reinvesting losses into research and development. Investors should note that profitability metrics and returns on equity are not meaningful given the company's net loss position.